Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if implitapide, used in conjunction with other lipid-lowering therapies, is safe and effective when compared to placebo in lowering low-density lipoprotein cholesterol (LDL-C) in patients with heterozygous familial hypercholesterolemia (HeFH).

Official Title
-----------------
Safety and Efficacy Study of Implitapide Compared With Placebo in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy

Conditions
-----------------
Familial Hypercholesterolemia

Intervention / Treatment
-----------------
* Drug: Implitapide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: In order to participate in this study, patients must meet all of the following inclusion criteria: be between 18 and 70 years old with a diagnosis of HeFH; be stable on and maintain concomitant therapy with hypolipidemic drugs or treatments; have an appropriate calculated, fasting LDL-C levels and an appropriate triglyceride (TG) level; be male or nonpregnant, nonlactating female; give informed consent; and meet body weight requirements. Exclusion Criteria: In order to participate in this study, patients must not meet any of the following exclusion criteria: recent myocardial infarction, percutaneous transluminal coronary intervention, coronary artery bypass graft surgery, or cerebrovascular accident; uncontrolled hypothyroidism or other uncontrolled endocrine disease; known, clinically significant eye abnormalities (e.g., cataracts); appropriate serum creatinine phosphokinase levels; history of liver disease or liver enzyme levels above appropriate levels; alkaline phosphatase above appropriate levels; serum creatinine above appropriate levels; liver cirrhosis and severe liver steatosis; clinically significant infection, malignancy, or psychosis; use of oral anticoagulants or digoxin, unless the dose has been stable for 4 weeks; participation in any other investigational study, including device or observational studies, within 30 days; lactating or have a positive serum pregnancy test; current drug or alcohol abuse; or unwillingness to comply with study procedures, including follow-up, as specified by this protocol, or unwillingness to cooperate fully with the investigator

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Implitapide|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Heterozygous Familial Hypercholesterolemia (HeFH)